coronavirus update indiaas on : 20 October 2020 05:22 GMT+5:30
China's Coronavirus Vaccine Is Safe,Produces Antibody Response
The second phase of the study was designed to identify the optimal timing schedule for vaccination.
China's Coronavirus Vaccine Is Safe, Produces Antibody Response
New Delhi: The Chinese coronavirus vaccine candidate BBIBP-CorV that is expected to completely inactivate the coronavirus, is safe and elicits an antibody response,published a study in The Lancet has found.
The previous clinical trial has reported the similar results for the different vaccine that is also based on the inactivated the whole SARS-CoV-2 virus, but the study the vaccine was only tested on people aged under 60 years.
In The Lancet Infectious Disease Journal, the latest study reported participants aged between 18 and 80 years and found that antibody responses were induced in all recipients.
The participants aged 60 and over were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59.
"Protecting older people is a key aim of a successful Covid-19 vaccine as this age group is at greater risk of severe illness from the disease," said study author Xiaoming Yang from the Beijing Institute of Biological Products Company Limited in China.
Vaccines however are sometimes less effective in this group because of the immune system weakness with the age.
"It is therefore encouraging to see that BBIBP-CorV induces antibody responses in people aged 60 and older, and we believe this justifies further investigation," Yang added.
In the study the BBIP-CorV vaccine used in the study reported here is based on a sample of the virus that was isolated from a patient in China.
BBIBP-CorV includes the killed virus mixed with another component, aluminum hydroxide, which is called an adjuvant because it is known to boost immune responses.
The first phase if the study was designed to find the optimal safe dose for BBIBP-CorV.
Also, it involved the 96 healthy volunteers aged between 18 and 59 years and the second group of 96 participants aged between 60 years and80 years.
Within each group, the vaccine was tested at three different dose levels, with two vaccinations administered on day zero and 28.
No serious adverse events were reported within 28 days of the final vaccination. There were no instances of clinically significant changes in organ functions detected in laboratory tests in any of the groups," the authors wrote.